Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neurology"
DOI: 10.1007/s00415-023-12103-4
Abstract: Nearly 60% of migraine patients treated with monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway experience a ≥ 50% reduction in monthly migraine days (MMD) at 12 weeks compared to baseline (responders). However, approximately half… read more here.
Keywords: anti cgrp; cgrp mabs; late responders; response ... See more keywords
Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria
Sign Up to like & getrecommendations! Published in 2024 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000538291
Abstract: Abstract Introduction: Two distinct chronic spontaneous urticaria (CSU) endotypes, IgE-mediated autoallergic and IgG-mediated autoimmune, were defined based on the response patterns to omalizumab. However, the coexistence of IgE and IgG autoantibodies in a subset of… read more here.
Keywords: speed response; late responders; response; spontaneous urticaria ... See more keywords
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter, Prospective, Observational Study.
Sign Up to like & getrecommendations! Published in 2023 at "Neurology"
DOI: 10.1212/wnl.0000000000207292
Abstract: OBJECTIVES To assess frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP). METHODS This is a multicenter (n=16), prospective, real-life study, considering all consecutive adults with… read more here.
Keywords: multicenter prospective; cgrp mabs; late responders; monoclonal antibodies ... See more keywords